Outcome of nucleos(t)ide analog intervention in patients with preventive or on‐demand therapy for hepatitis B virus reactivation
- 17 September 2020
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (6) , 3679-3687
Abstract
Preventive or on‐demand nucleos(t)ide analog (NA) therapy can prevent severe hepatitis related to hepatitis B virus reactivation (HBV‐R). However, it is unclear if NA can be safely stopped in such patients after cytotoxic therapies or during immunosuppressive therapies. We retrospectively evaluated 133 patients who initiated NA therapy between 2007 and 2018. A total of 103 patients were positive for HBV surface antigen (HBsAg) at baseline, and NA therapy was started before cytotoxic or immunosuppressive therapy (preventive group). Thirty patients with resolved HBV infection were treated with NA therapy after HBV reactivation (on‐demand group). Virological relapse was defined as a serum HBV DNA level >20 IU/ml. NA therapy was stopped in 12 (12%) patients (preventive group), and in 16 (53%) patients (on‐demand group). After the cessation of NA therapy, the cumulative rates of relapse were 36% and 39% at 12 and 24 months, respectively. High levels of HBsAg both at baseline and at the cessation of NA therapy were related to the occurrence of relapse. Relapse did not occur in patients with HBsAg levels <20 IU/ml (preventive group). HBV relapse occurred in five (33%) patients in the on‐demand group. Relapse occurred only in anti‐HBs‐negative patients at the cessation of NA therapy. There were no cases of hepatitis flare after the cessation of NA therapy. HBsAg predicted HBV relapse after the cessation of NA therapy in HBsAg‐positive patients. Anti‐HBs could be a predictive marker for NA therapy cessation in patients with resolved HBV.Keywords
Funding Information
- Japan Agency for Medical Research and Development (18950494)
This publication has 18 references indexed in Scilit:
- Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational StudyClinical Infectious Diseases, 2015
- American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug TherapyGastroenterology, 2015
- Prospective long‐term study of hepatitis B virus reactivation in patients with hematologic malignancyJournal of Gastroenterology and Hepatology, 2014
- Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis BHepatology Research, 2013
- HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virusJournal of Hepatology, 2010
- HB Vaccination in the Prevention of Viral Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Previous HBV InfectionTransplantation and Cellular Therapy, 2008
- COBAS AmpliPrep-COBAS TaqMan Hepatitis B Virus (HBV) Test: a Novel Automated Real-Time PCR Assay for Quantification of HBV DNA in PlasmaJournal of Clinical Microbiology, 2007
- Hepatitis B Virus Reactivation After Cytotoxic Chemotherapy: The Disease and Its PreventionClinical Gastroenterology and Hepatology, 2006
- Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapyBlood, 2003
- Sensitive Enzyme Immunoassay for Hepatitis B Virus Core-Related Antigens and Their Correlation to Virus LoadJournal of Clinical Microbiology, 2002